Investigating how tumor cell interactions with macrophages affect resistance to prostate cancer therapy
Official title: Targeting tumor cell macrophage lipid interactions to overcome resistance to androgen receptor targeted therapy
Funded at Indiana University Indianapolis · NIH-10651105 · Data updated 2026-11-12
This study is looking at how certain immune cells in the body might make prostate cancer tougher to treat with common therapies, and by understanding this, the researchers hope to find better ways to help patients like you respond to treatment.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project start | September 14, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $423,130 |
| NIH project number | 1R21CA270913-01A1 |
| Project ID | NIH-10651105 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with prostate cancer who are undergoing androgen receptor-targeted therapy.
✕Less likely to help
Patients with non-prostate cancers or those not receiving androgen receptor-targeted therapies may not benefit from this research.
What this research studies
This research focuses on understanding how tumor-associated macrophages, a type of immune cell, contribute to the resistance of prostate cancer to androgen receptor-targeted therapies. By analyzing the interactions between these macrophages and cancer cells, the study aims to uncover the metabolic changes that promote cancer growth and therapy resistance. The researchers will use advanced techniques to explore how cholesterol metabolism and other factors influence these interactions, potentially leading to new therapeutic strategies. Patients may benefit from insights that could improve treatment outcomes for prostate cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for prostate cancer by overcoming resistance to current therapies.
How similar studies have gone: Other research has shown promising results in targeting immune cell interactions in cancer, suggesting that this approach may yield significant insights.
Where this research is happening
-
Indiana University Indianapolis
Indianapolis, United States Active
Researchers
- Principal investigator: Elkenawi, Asmaa — Indiana University Indianapolis
- Study coordinator: Elkenawi, Asmaa
Related research
Other NIH-funded projects on the same topics.
-
Integrative histo-genomic analysis to guide cancer risk and targeted therapies with interpretable AI
Researchers are developing an advanced AI-powered approach to map genetic and cellular patterns across breast and cervical cancers to help tailor treatments.
-
Targeted therapy for AML using DHODH inhibitors to boost differentiation and immune response
Aims to help adults with acute myeloid leukemia by using a special drug approach that makes cancer cells act more like normal blood cells and supports the immune system.
-
Adipome biomarkers in obese TNBC mice for targeted therapy
A study in mice explores how fat-derived particles called adipomes influence an aggressive breast cancer type, with the goal of guiding personalized therapies.
-
Enhancing HER2-targeted therapy for resistant breast cancer
This grant explores new ways to overcome resistance to HER2-targeted therapy in people with HER2-positive breast cancer.
-
Metabolic imaging to guide targeted therapy for liver cancer
A clinician-scientist at UPenn is pursuing training to use metabolic imaging to tailor therapy for hepatocellular carcinoma.
-
Targeted therapy for splicing-factor mutant myeloid cancers
Aims to test a dual drug strategy targeting ATR and PARP pathways in adults with splicing-factor mutant acute myeloid leukemia or related myeloid diseases.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.